Selank

Cognitive Research compound (not approved for human use)

Synthetic heptapeptide (tuftsin analog) · also known as Selank nasal

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Selank is a stabilized analog of tuftsin, a naturally occurring tetrapeptide, extended with a Pro-Gly-Pro sequence. It was developed in Russia and examined mainly as an intranasal preparation in anxiety-spectrum conditions. Subcutaneous use is also commonly reported outside the formal literature.

Commonly reported dosing (5 mg vial)

Reconstituted with 5 mL → 1 mg/mL.

Also sold in 10 mg vials.

Phase	Dose	Volume	U-100 units
Standard	300 mcg	0.3 mL	30

Frequency: 3x daily, intranasal · Half-life: Short in plasma (minutes); route dependent

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
5 mL of sterile water is added slowly down the inside wall of the 5 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 1 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen or refrigerated and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated and not frozen; registered nasal products are labeled for storage at no more than 10 °C.

Commonly used within 28 days of mixing.

How it works

Preclinical work suggests Selank modulates GABAergic signaling, monoamine metabolism, and BDNF expression, and it has reported effects on immune-related cytokines. The exact receptor-level mechanism is not settled.

Researched for

Studied in small human trials against anxiety and asthenic disorders, including comparison with phenazepam.
Examined in animal models for anxiolytic and antidepressant-like behavior.
Investigated for immune-modulating effects alongside its behavioral actions.

Notes

Published human work mainly used an intranasal 0.15% drop formulation, with daily amounts around 2,700 mcg in some trials; the 300 mcg three-times-daily figure comes from the reference chart.
The nasal preparation is normally made up in a sterile saline-type vehicle rather than bacteriostatic water.
Registered as a medicine in Russia; not FDA-approved.
Most evidence is from Russian-language trials and animal work.